Icaritin induces paraptosis in hepatocellular carcinoma cells by targeting BHLHE40 via endoplasmic reticulum stress and mitochondrial dysfunction

  • Phytomedicine. 2025 Jul 25:143:156870. doi: 10.1016/j.phymed.2025.156870.
Wencheng Wei  1 Hao Wang  2 Li Fu  3 Hui Liu  4
Affiliations
  • 1. Department of Hepatobiliary Surgery, Shenzhen University General Hospital & Shenzhen University Clinical Medical Academy Center, Shenzhen University, Shenzhen 518067, PR China; Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen 518060, PR China; Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pharmacology and International Cancer Center, Shenzhen University Medical School, Shenzhen 518060, PR China.
  • 2. Maternal-Fetal Medicine Institute, Department of Obstetrics and Gynecology, Shenzhen Baoan Women's and Children's Hospital, Shenzhen University, Shenzhen, PR China.
  • 3. Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pharmacology and International Cancer Center, Shenzhen University Medical School, Shenzhen 518060, PR China. Electronic address: [email protected].
  • 4. Department of Hepatobiliary Surgery, Shenzhen University General Hospital & Shenzhen University Clinical Medical Academy Center, Shenzhen University, Shenzhen 518067, PR China. Electronic address: [email protected].
Abstract

Objective: Icaritin, a flavonoid derived from the traditional Chinese medicine Epimedium, exhibits diverse biological activities; however, the mechanisms underlying its effects against hepatocellular carcinoma (HCC) remain unclear. This study aimed to investigate the Anticancer properties of icaritin and elucidate the mechanisms of icaritin-induced cell death.

Methods: The effects of icaritin-induced Paraptosis were assessed using CellTiter-Glo, EdU, and colony formation assays, and phenotypic observations. Transcriptome analysis was performed to identify the dysregulated genes associated with icaritin-induced Paraptosis. Western blotting and qRT-PCR were used to analyze icaritin-induced changes in protein and mRNA levels, respectively. Mito-GFP, ROS, and MMP assays were conducted to monitor the mitochondrial status. IPA, molecular docking, CETSA, shRNA and cell-derived xenografts confirmed the role of BHLHE40 in icaritin-induced Paraptosis in vivo and in vitro RESULTS: Icaritin induced Paraptosis in HCC cells, which was characterized by cytoplasmic vacuolation and caspase-independent. Transcriptomic analysis indicated that icaritin triggered ER stress and mitochondrial dysfunction, validated by molecular and biochemical assays. IPA, molecular docking, and CETSA analyses identified BHLHE40 as a crucial mediator of this process. BHLHE40 knockdown inhibited ER stress and mitochondrial dysfunction, significantly reducing icaritin-induced Paraptosis in HCC cells. Animal experiments demonstrated that silencing of BHLHE40 diminished the inhibitory effects of icaritin on tumor growth in xenograft models.

Conclusion: These results highlight the potent Anticancer effects of icaritin, particularly its ability to induce Paraptosis by targeting BHLHE40. This study provides a comprehensive understanding of the Anticancer mechanisms of icaritin and suggests that targeting BHLHE40 represents a novel therapeutic strategy for enhancing the efficacy of Cancer treatment.

Abbreviations: HCC: Hepatocellular carcinoma; TCM: Traditional Chinese Medicine; ER: Endoplasmic Reticulum; MMP: Mitochondrial Membrane Potential; ROS: Reactive Oxygen Species; CTG: CellTiter-Glo; EdU: 5-ethynyl-2'-deoxyuridine; UPR: Unfolded Protein Response; BHLHE40: Basic helix-loop-helix family member E40; IPA: Ingenuity Pathway Analysis; CETSA: Cellular Thermal Shift Assay; PI: Propidium Iodide;PCR: Polymerase Chain Reaction; qRT-PCR: Quantitative Reverse Transcription PCR; GFP: Green Fluorescent Protein; JC-1: 5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide; ATF4: Activating Transcription Factor 4; PERK: Protein kinase RNA-like ER kinase; DDIT3: DNA Damage Inducible Transcript 3; LMNA: Lamin A/C; IC50: Half Maximal Inhibitory Concentration; PEG300: Polyethylene glycol 300; PBS: Phosphate Buffered Saline; BSA: Bovine Serum Albumin; HRP: Horseradish Peroxidase; SRA: Sequence Read Archive; PCD: Programmed Cell Death; COX8A: Cytochrome c oxidase subunit 8A; DCFH-DA: 2',7'-Dichlorodihydrofluorescein diacetate; CHX: Cycloheximide; zVAD-FMK: Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone; PARP: Poly (ADP-ribose) polymerase; DMSO: Dimethyl sulfoxide; SPF: Specific Pathogen-Free; IACUC: Institutional Animal Care and Use Committee.

Keywords
Bhlhe40; Er stress; Hepatocellular carcinoma; Icaritin; Paraptosis.
Products